16-Year Experience at M. D. Anderson Cancer Center with Primary Ki-1 (CD30) Antigen Expression and Anaplastic Morphology in Adult Patients with Diffuse Large Cell Lymphoma

References

• Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., Diehl V. Production of monoclonal antibody specific for Hodgkin's and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299: 65–67
   PubMed Web of Science ®Google Scholar
• Stein H., Mason D. Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., Schwarting R., Lennert K. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–858
   PubMed Web of Science ®Google Scholar
• Jones D. B., Gerdes J., Stein H., Wright D. H. An investigation of Ki-1 positive large cell lymphoma with antibodies reactive with tissue macrophages. Hematol. Oncol. 1986; 4: 315–322
   PubMed Web of Science ®Google Scholar
• Greer J. P., Kinney M. C., Collins R. D., Salhany K. E., Wolff S. N., Hainsworth J. D., Flexner J. M., Stein R. S. Clinical features of 31 patients with Ki-1 anaplastic large cell lymphoma. J. Clin. Oncol. 1991; 9: 539–547
   PubMed Web of Science ®Google Scholar
• Delsol G., Al Saait T., Gatter K. C., Gerdes J., Schwarting R., Caveriviere P., Rigal-Huguet F., Robert A., Stein H., Mason D. Y. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 (IL-2) receptor by anaplastic large cell lymphomas. Diagnostic value in so called malignant histiocytosis. Am. J. Pathol. 1987; 40: 995–1015
   Google Scholar
• Suchi T., Lennert K., Kikuchi M., Sato E., Stansfeld A. G., Feller A. C. Histopathology and immunohistochemistry of peripheral T cell lymphomas: A proposal for their classification. J. Clin. Pathol. 1987; 40: 995–1015
   PubMed Web of Science ®Google Scholar
• Stansfeld G., Diebold J., Kapanci Y., Rilke F., KelÉNyi G., Sundstrom C., Lennert K., Van Unnik J. A., Mioduszewska O., Wright D. H. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293
   PubMed Web of Science ®Google Scholar
• Chan J. K. C., Ng C. S., Hiu P. K., Leungs T. W., Lo E. S. F., Lau W. H., McGuire L. J. Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological subtypes. Histopathol. 1989; 15: 11–34
   PubMed Web of Science ®Google Scholar
• Chott A., Kaserer K., Augustin I., Vesely M., Heinz R., Oehlinger W., Hanak H., Radaszkiewicz T. Ki-1 positive large cell lymphoma: A clinicopathologic study of 41 cases. Am. J. Surg. Pathol. 1990; 14: 439–448
   PubMed Web of Science ®Google Scholar
• Agnarsson B. A., Kadin M. E. Ki-1 positive large cell lymphomas: A morphologic and immunologic study of 19 cases. Am. J. Surg. Pathol. 1988; 21: 264–274
   Web of Science ®Google Scholar
• Kadin M. E., Sako D., Berliner N., Franklin W., Woda B., Borowitz M., Ireland K., Schweid A., Herzog P., Lange B., Dorfman R. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral adenopathy. Blood 1986; 60: 1042–1049
   Google Scholar
• Offit K., Ladanyi M., Gangi M. D., Ebrahim S. A. D., Filippa D., Changanti R. S. K. Ki-1 antigen expression defined a favorable clinical subset of non-B cell non-Hodgkin's lymphoma. Leukemia 1990; 4: 625–630
   PubMed Web of Science ®Google Scholar
• Romaguera J. E., Hagemeister F. B., McLaughlin P., Swan F., Velasquez W., Rodriguez M., Redman J., Cabanillas F. (1978) 1990 Adult Ki-1 positive diffuse large cell lymphoma (DLCL) A distinct clinicopathological entity with favorable prognosis. In. Proceedings of the American Society of Clinical Oncology, vol. 9, p. 216. 1990
   Google Scholar
• Shulman L., Frisard B., Antin J. H., Wheeler C., Pinkus G., Magauran N., Mauch P., Nobles E., Mashal R., Canellos G., Tung N., Kadin M. Primary anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome. J. Clin. Oncol. 1993; 11: 937–43
   PubMed Web of Science ®Google Scholar
• Nakamura S., Takagi N., Kojima M., Motoori T., Kitoh K., Asada H., Suzuki H., Ogura M., Kurita S., Oyama A., Ueda R., Takahashi T., Suchi T. Clinicopathologic study of large-cell anaplastic lymphoma (Ki-1-positive large-cell lymphoma) among the Japanese. Cancer 1991; 68: 118–129
   PubMed Web of Science ®Google Scholar
• Kadin M. E. Ki-1/CD30+ (anaplastic) large-cell lymphoma: Maturation of a clinicopathologic entity with prospects of effective therapy. J. Clin. Oncol. 1994; 12: 884–887
   PubMed Web of Science ®Google Scholar
• Kadin M. E. Primary Ki-1 -positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity. Ann. Oncol. 1994; 5: 25–30
   PubMed Web of Science ®Google Scholar
• D'Agay M. F., BriÈRe J., Lepage E., Herbrecht R., Morel P., Tilly H., Symann M., Reyes F., Gaulard P., Delsol G., Diebold J., Coiffier B. 1993 Anaplastic large cell lymphoma in adults: A study of 140 cases with comparison to a cohort of 1225 non-anaplastic large cell lymphomas included in the same LNH 87 protocol. Proceedings of the Fifth International Conference on Malignant Lymphomas, Lugano, Switzerland, p. 74 (abstract P15). 1978
   Google Scholar
• Greer J. P., Whitlock J. A., Macon W. R., Flexner J. M., Stein R. S., Wolff S. N., Hainsworth J. D., Collins R. D., Kinney M. C. (1978) 1993 Primary Ki-1 lymphoma: Clinicopathologic features of 58 patients. Proceedings of the American Society of Hematology, Vol. 12, p. 366. 1993
   Google Scholar
• Pileri S., Bocchia M., Baroni C. D., Martelli M., Falini B., Sabattini E., Gherlinzoni F., Amasori S., Simonetta P., Mazza P., Burgio V., Zinzani P. L., Melilli G., Benni M., Saragoni L., Martelli M. F., Stein H., Mandelli F., Tura S. Anaplastic large cell lymphoma (CD30+/Ki-1+) Results of a prostpective clinico-pathological study of 69 cases. Br. J. Haematol. 1994; 86: 513–523
   PubMed Web of Science ®Google Scholar
• Penny R. J., Blaustein J. C., Longtine J. A., Pinkus G. S. Ki-1 positive large cell lymphomas, a heterogenous group of neoplasms: Morphological, immunophenotypic, genotypic, and clinical features of 24 cases. Cancer 1991; 68: 362–373
   PubMed Web of Science ®Google Scholar
• Romaguera J. E., Manning J. T., Tornos C., Rodriguez R., Brooks T. E., Pugh W. C., OrdoÑEz N. G., Goodacre A. M., Cabanillas F. Long term prognostic importance of primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma. Ann. Oncol. 1994; 5: 317–322
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Rodriguez J. E., Cabanillas F., McLaughlin P., Swan F., Rodriguez M., Hagerneister F., Romaguera J. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the “tumor score.”. Ann. Oncol. 1992; 3, 711–717
   Web of Science ®Google Scholar
• Peto R., Peto J. Asymptotically efficient rank invariant test procedures. J. R. Stat. Soc. 1972; 35: 185–207
   Google Scholar
• Hsu S. M., Raines L., Fanger H. Use of avidin-biotinperoxidase complex (ABC) and immunoperoxidase technique: Comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 1991; 29: 577–580
   Web of Science ®Google Scholar
• Sandlund J. T., Ching-Hon P., Santana V. M., Mahmoud H., Roberts W. M., Morris S., Raimondi S., Ribeiro R., Crist W. M., Lin J.-S., Mao L., Berard C. W., Hutchison R. E. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 1994; 12: 895–898
   PubMed Web of Science ®Google Scholar
• Salhany K. E., Collins R. D., Greer J. P., Kinney M. C. Long-term survival in Ki-1 lymphoma. Cancer 1991; 67: 516–522
   PubMed Web of Science ®Google Scholar
• Gruss H-J., Boiani N., Williams D. E., Armitage R. J., Smith C. A., Goodwin R. G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045–2056
   PubMed Web of Science ®Google Scholar
• Pasqualucci L., Wasik M. A., Teicher B., Martelli M. F., Falini B., Kadin M. E. In vivo antitumor activity of Ber-H2 (CD30)/Saporin immunotoxin against human Ki-1+ anaplastic large cell lymphoma in SCID mice. Blood 1993; 82: 534a
   Web of Science ®Google Scholar
• Kehrl J. H., Wakefield L. M., Roberts A. B., Jakowlew S., Alvarez-Mon M., Derynck R., Spom M. B., Fauci A. S. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T-cell growth. J. Exp. Med. 1986; 163: 1037–1050
   PubMed Web of Science ®Google Scholar
• Kehrl J. H., Roberts A. B., Wakefield L. M., Jakowlew S., Spom M. B., Fauci A. S. Transofrming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 1986; 137: 3855–3860
   PubMed Web of Science ®Google Scholar
• Newcom S. R., Kadin M. E., Ansari A. A. Production of transforming growth factor-beta activity by Ki-1 positive lymphoma cells and analysis of its role in the regulation of Ki-1 positive lymphoma growth. Am. J. Pathol. 1988; 131: 569–577
   PubMed Web of Science ®Google Scholar
• Newcom S. R., Tagra K. K., Kadin M. E. Neutralizing antibodies against transforming growth factor β potentiate the proliferation of Ki-1 positive lymphoma cells. Am. J. Pathol. 1992; 140: 709–738
   PubMed Web of Science ®Google Scholar
• Wasik M. A., Sioutos N., Tuttle M., Butmare J. R., Kaplan W. D., Kadin M. E. Constitutive secretion of soluble inter-leukin-2 receptor by human T-cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice. Am. J. Pathol. 1994; 144: 1089–1097
   PubMed Web of Science ®Google Scholar
• Gause A., Jung W., Schmits R., Tschiersch A., Scholz R., Pohl C., Hasenclever D., Diehl V., Pfreundschuh M. Soluble CD8, CD25, and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann. Oncol. 1993; 3: 49–52
   Web of Science ®Google Scholar
• Piris M., Brown D. C., Gatter K. C., Mason D. Y. CD30 expression in non-Hodgkin's lymphoma. Histopathol. 1990; 17: 211–218
   PubMed Web of Science ®Google Scholar
• Bitter M. A., Franklin W. A., Larson R. A. Morphology in Ki-1 (CD30) positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5) (p23;q35). Am. J. Surg. Pathol. 1990; 14: 305–316
   PubMed Web of Science ®Google Scholar
• Baeak V., Ginzburg M., Kalickman I., Polliack A. Serum soluble IL-2 ???p. 12 levels are associated with clinical disease status histopathologic grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Leukemia & Lymphoma 1992; 7: 431–438
   PubMed Web of Science ®Google Scholar